Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer.
Cima I, Schiess R, Wild P, Kaelin M, Schüffler P, Lange V, Picotti P, Ossola R, Templeton A, Schubert O, Fuchs T, Leippold T, Wyler S, Zehetner J, Jochum W, Buhmann J, Cerny T, Moch H, Gillessen S, Aebersold R, Krek W. Cima I, et al. Among authors: schiess r. Proc Natl Acad Sci U S A. 2011 Feb 22;108(8):3342-7. doi: 10.1073/pnas.1013699108. Epub 2011 Feb 7. Proc Natl Acad Sci U S A. 2011. PMID: 21300890 Free PMC article.
Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07).
Cathomas R, Rothermundt C, Klingbiel D, Bubendorf L, Jaggi R, Betticher DC, Brauchli P, Cotting D, Droege C, Winterhalder R, Siciliano D, Berthold DR, Pless M, Schiess R, von Moos R, Gillessen S; Swiss Group for Clinical Cancer Research SAKK. Cathomas R, et al. Among authors: schiess r. Clin Cancer Res. 2012 Nov 1;18(21):6049-57. doi: 10.1158/1078-0432.CCR-12-2219. Epub 2012 Sep 12. Clin Cancer Res. 2012. PMID: 22977195 Clinical Trial.
Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08).
Templeton AJ, Dutoit V, Cathomas R, Rothermundt C, Bärtschi D, Dröge C, Gautschi O, Borner M, Fechter E, Stenner F, Winterhalder R, Müller B, Schiess R, Wild PJ, Rüschoff JH, Thalmann G, Dietrich PY, Aebersold R, Klingbiel D, Gillessen S; Swiss Group for Clinical Cancer Research (SAKK). Templeton AJ, et al. Among authors: schiess r. Eur Urol. 2013 Jul;64(1):150-8. doi: 10.1016/j.eururo.2013.03.040. Epub 2013 Apr 6. Eur Urol. 2013. PMID: 23582881 Clinical Trial.
Similarities and Differences of Blood N-Glycoproteins in Five Solid Carcinomas at Localized Clinical Stage Analyzed by SWATH-MS.
Sajic T, Liu Y, Arvaniti E, Surinova S, Williams EG, Schiess R, Hüttenhain R, Sethi A, Pan S, Brentnall TA, Chen R, Blattmann P, Friedrich B, Niméus E, Malander S, Omlin A, Gillessen S, Claassen M, Aebersold R. Sajic T, et al. Among authors: schiess r. Cell Rep. 2018 May 29;23(9):2819-2831.e5. doi: 10.1016/j.celrep.2018.04.114. Cell Rep. 2018. PMID: 29847809 Free article.
PROPOSe: A Real-life Prospective Study of Proclarix, a Novel Blood-based Test to Support Challenging Biopsy Decision-making in Prostate Cancer.
Steuber T, Heidegger I, Kafka M, Roeder MA, Chun F, Preisser F, Palisaar RJ, Hanske J, Budaeus L, Schiess R, Keller T, Semjonow A, Hammerer P, Manka L, Ecke T, Schwentner C, Ohlmann C. Steuber T, et al. Among authors: schiess r. Eur Urol Oncol. 2022 Jun;5(3):321-327. doi: 10.1016/j.euo.2020.12.003. Epub 2021 Jan 6. Eur Urol Oncol. 2022. PMID: 33422560
A novel serum biomarker quintet reveals added prognostic value when combined with standard clinical parameters in prostate cancer patients by predicting biochemical recurrence and adverse pathology.
Athanasiou A, Tennstedt P, Wittig A, Huber R, Straub O, Schiess R, Steuber T. Athanasiou A, et al. Among authors: schiess r. PLoS One. 2021 Nov 12;16(11):e0259093. doi: 10.1371/journal.pone.0259093. eCollection 2021. PLoS One. 2021. PMID: 34767586 Free PMC article.
47 results